Every plan we write starts from the same question: what do independent health systems, working from different guidelines and different populations, actually agree on — and where do they genuinely differ? Here's where that picture comes from.
Every country's clinical guidelines carry the fingerprints of that country's health system: how it's paid for, what it screens for by default, which risks it's built to catch early and which it isn't. Reading only one system's guidelines means inheriting its blind spots.
North America, Northern Europe, and East Asia were chosen deliberately: three systems with genuinely different institutional habits, deep enough research bases to be worth tracking on their own, and — critically — different enough from each other that agreement between them means something.
US and Canadian systems favor early, frequent screening and draw on the largest pharmaceutical and biotech research base in the world. The tradeoff is a guideline culture that moves quickly — sometimes ahead of the underlying evidence — and preventive care that's excellent for people who can access it and inconsistent for people who can't. We lean on North American research heavily for anything drug- or device-related, and treat its newest guideline updates as leading indicators worth watching rather than settled conclusions.
Nordic and UK-adjacent systems are typically more conservative about adopting new interventions, but they compensate with some of the best long-term population health registries anywhere — decades of linked outcomes data that's hard to replicate. When we want to know what actually happens to an outcome twenty years after an intervention, rather than what a five-year trial suggests, this is usually where we look first.
Japan, South Korea, and Singapore run some of the largest population-level studies anywhere on metabolic health and healthy aging, shaped by their own demographics, and tend to integrate routine, low-cost screening into primary care more thoroughly than the other two regions. We track this closely for anything metabolic, and increasingly for cognitive aging as that research matures.
Dr. Marcus Adeyemi's research team reviews new clinical literature and guideline updates from all three regions on a running basis, and maintains working relationships with colleagues practicing in each one.
When the three regions agree on something, we treat that agreement as a strong signal — it's usually a better predictor than any single study. When they genuinely differ, that's often the most interesting part of the research, and a sign the evidence is still unsettled. We say so in client plans rather than picking a side prematurely to sound more confident than the data supports.
Formal research relationships outside North America began in Northern Europe in 2020; East Asia followed as the team grew. See the full timeline on our approach page.
See how global synthesis becomes a single personalized plan.
Read our approach